# The JenaValve ALIGN-AR Pivotal Trial

Study · id `cardio:ct-nct04415047` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04415047](<https://clinicaltrials.gov/study/NCT04415047>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04415047

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 180 participants.

## Technical summary

Registry record NCT04415047. Allocation not applicable; no masking; primary purpose treatment. Start 2020-05-22 (actual); primary completion 2023-08-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT04415047, source copy `cardio:ctgov-nct04415047-2022-09-13`, retrieved 2026-10-26)
- Started: 2020-05-22 (actual) (ClinicalTrials.gov record NCT04415047, source copy `cardio:ctgov-nct04415047-2022-09-13`, retrieved 2026-10-26)
- Primary completion: 2023-08-29 (anticipated) (ClinicalTrials.gov record NCT04415047, source copy `cardio:ctgov-nct04415047-2022-09-13`, retrieved 2026-10-26)
- Completion: 2028-08 (anticipated) (ClinicalTrials.gov record NCT04415047, source copy `cardio:ctgov-nct04415047-2022-09-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04415047, source copy `cardio:ctgov-nct04415047-2022-09-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04415047-2022-09-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: The JenaValve ALIGN-AR Pivotal Trial
- Acronym: ALIGN-AR
- Condition: Aortic Regurgitation
- Condition: Aortic Valve Insufficiency
- Condition: Aortic Insufficiency
- Condition: Aortic Valve Disease
- Intervention (Device): JenaValve Trilogy Heart Valve System
- Lead sponsor: JenaValve Technology, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: JenaValve Technology, Inc. (`cardio:org-jenavalve-technology-inc`)

## Provenance

Content hash: c18f7e3c2c464c78197c365ef79b9d91a54fc2836bdf477c7005456b1e83c144
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
